The Effect of Umbilical Cord-derived Mesenchymal Stem Cell Transplantation in a Patient with Cerebral Palsy: A Case Report

Abstract

BackgroundCerebral Palsy (CP) is the most common motor disability reason of childhood that occurs secondarily to non-progressive damage in the brain whose development is still ongoing.Methods6-year-old dystonic-spastic male CP patient received allogenic mesenchymal stem cells treatment four times as 1×106/kg in intrathecal and intravenous administration of Umbilical Cord-derived mesenchymal stem cells (UC-MSCs) ways. Before and after the treatment, the patient was followed-up with FIM (Functional Independent Measurement), GMFCS (Gross Motor Function Classification System 88), Tardieu Scale, TCMS (Trunk Control Measurement Scale), MACS (Manual Ability Classification Scale), CFSS (Communication Function Classification System) for 18 months and received intensive rehabilitation.ResultsImprovements were observed especially in functional scales except for the Tardieu Scale, and no adverse effects were detected aside from a slight pain in the back.ConclusionWider future case studies on UC-MSCs will enable us to assess the efficacy of UC-MSCs which have positive impacts especially on functional scales.

Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial

“…The improvements were likely related to the anti-inflammatory potential of hUC-MSCs since IL-1α, IL-6, and TNF-β were decreased significantly after transplantation [46]. When considering the transplantation route of cell therapy, intravenous administration was preferred to intrathecal injection for better compliance, since pain at the injection site was a complaint due to intrathecal administration [16]. In addition, hUC-MSCs were given at dosages of 4.5~5.5 × 10 7 cells intravenously in our study, which was supported by the suggested doses in the Clinical Cell Therapy Guidelines for Neurorestoration [47].…”

“…Functional improvements with alleviation of brain lesions were detected after hUC-MSC transplantation in a series of animal model studies [13][14][15]. In clinical case reports, gross motor and cognitive functions were improved after hUC-MSC [16] and bone marrow mononuclear cell transplantation [17]. In addition, gross motor function classification scores were promoted significantly after human embryonic stem cell treatment in a retrospective cohort analysis [18].…”

Improving effects of mesenchymal stem cells on symptoms of chronic obstructive pulmonary disease

“…Umbilical cord tissuederived MSCs, which were manufactured under cGMP (current Good Manufacturing Practice) conditions (LivMedCellIstanbul, Turkey) were used in this study. Cell preparation steps were performed according to cGMP requirements as described previously (11,12). The cells were characterized by identifying the potential for differentiation using a fl ow cytometer and immunohistochemical analysis, cell aging, cell cycle, annexin V/PI and telomerase enzyme activity at the third passage.…”

Mesenchymal stromal cells as a potential therapeutic for neurological disorders

“…(2016) [54] Spinal cord injury AD 14 41.9 (20–66) IT 9 × 10 7 cells at 1-month interval 2 Motor (5/14) and sensory (10/14) functional recovery after 8 months Nausea, vomit, head ache Okur SC et al. (2018) [64] Cerebral palsy UC 1 6 IT 1 × 10 6 /kg 4 Motor functional recovery after 18 months Back pain IV 1 × 10 6 /kg Wang et al. (2015) [15] Cerebral palsy UC 16 (8 twins) 6.29 (3–12) IT 1–1.5 × 10 7 cells at 3–5 days interval 4 Motor functional recovery after 1 & 6 months No Cheng H et al.…”